Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

DOCSBullishIndustry Newsnews

High materiality7/10

Doximity AI platform outperforms frontier models in NOHARM safety benchmark

Jul 15, 2026, 2:29 PM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Independent, third-party safety validation can improve procurement confidence and accelerate deals; however, no immediate revenue data exists and reactions depend on subsequent bookings and deployments.

AI summary

What happened, with direct paths to the underlying reporting

An independent ARISE study led by Stanford and Harvard found Doximity Ask ranked first among AI systems on a real-world clinical sample, outranking OpenEvidence, GPT-5.6 Sol and Claude Fable 5. The result reinforces Doximity's physician-first, HIPAA-compliant approach and could accelerate enterprise adoption across health systems, boosting long-term revenue potential if demand scales.

Doximity Ask outperformed frontier models in the NOHARM benchmark.
ARISE Stanford/Harvard study evaluated AI safety with simulated cases.
PeerCheck program includes >11,000 cited physician experts validating outputs.
Clinical AI Suite deployed across >150 health systems, including eight of top-20 hospitals.
NOHARM tests covered 1,100+ scenarios across 10 specialties.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Doximity AI platform outperforms frontier models in NOHARM safety benchmark

Doximity climbs after Q1 guidance raise and AI monetization potential

BofA Downgrade Highlights AI Costs and Soft Demand for Doximity

Doximity Misses Earnings Forecasts Amid Downgrades and Weak Growth Outlook

Doximity Earnings Report Expected to Show Year-Over-Year Decline